Novel menin-KMT2A inhibitor appears to be safe and well-tolerated. FLT3 inhibitor plus low-dose chemotherapy shows promising efficacy and safety. Results represent encouraging news on hard-to-treat ...
The FDA has approved a supplemental New Drug Application (sNDA) to update the product labeling for Xospata (gilteritinib; Astellas Pharma) to include final analysis data from the ADMIRAL trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results